Nemaura Medical (NSDQ:NMRD) said today that it successfully developed predictive algorithms to support alarm functions in its sugarBeat continuous glucose monitoring system.
The England-based company touted that its device’s alarm functionality can predict a user’s glucose level five minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with 90% accuracy.
Nemaura expects to win CE Mark approval for the wearable sugarBeat system in the coming weeks, at which time it will launch in the U.K.
In August, Nemaura kicked off a study of its sugarBeat system and touted positive interim data from the trial, focusing on the at-home use of the device.
Interim results from the study included findings from 25 patients with either Type 1 or Type 2 diabetes who wore the sugarBeat product for one or two non-consecutive days. Each participant also recorded up to five blood glucose readings via finger-pricks per day.
Researchers found that data from the sugarBeat product compared favorably with data gleaned from commercial continuous glucose monitors.
The company’s U.S. study is slated to enroll 75 people who will wear the device over a 7-day period. Nemaura plans to finish the study and submit an application to the FDA for regulatory approval in the first quarter of 2019.
